Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, fu...
02:49 ETGenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub
Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rate
RINGPU: A pilot production line for mycelium protein has been established, providing a foundation for industrialization and promotion conditions
RINGPU: "Double Eleven" pet-related work has been fully promoted
RINGPU released its performance for the first three quarters, with a net profit attributable to the parent company of 362 million yuan, an increase of 45.64%
RINGPU: The net profit for the third quarter was 106 million yuan, a year-on-year increase of 23.02%